PF 05175157

• CAT Number: I008675
• CAS Number: 1301214-47-0
• Molecular Formula: C23H27N5O2
• Molecular Weight: 405.50
• Purity: ≥95%
• Synonyms: PF-05175157; PF05175157; PF 05175157.;1,4-Dihydro-1/’-[(2-methyl-1H-benzimidazol-6-yl)carbonyl]-1-(1-methylethyl)-spiro[5H-indazole-5,4/’-piperidin]-7(6H)-one
• Target: Acetyl-CoA Carboxylase
• Solubility: Soluble in DMSO, not in water
• Storage: Store at -20°C
• IC50: 33 nM
• IUPAC Name: 1'-(2-methyl-3H-benzimidazole-5-carbonyl)-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-7-one
• InChI: InChI=1S/C23H27N5O2/c1-14(2)28-21-17(13-24-28)11-23(12-20(21)29)6-8-27(9-7-23)22(30)16-4-5-18-19(10-16)26-15(3)25-18/h4-5,10,13-14H,6-9,11-12H2,1-3H3,(H,25,26)
• InChIKey: BDXXSFOJPYSYOC-UHFFFAOYSA-N
• SMILES: CC1=NC2=C(N1)C=C(C=C2)C(=O)N3CCC4(CC3)CC5=C(C(=O)C4)N(N=C5)C(C)C

PF-05175157（Cat No.:I008675）is an experimental drug developed by Pfizer, primarily designed as a selective inhibitor of the protein S1P1 receptor. The drug has been investigated for its potential in treating autoimmune diseases such as multiple sclerosis (MS) and inflammatory bowel diseases (IBD) by modulating immune cell trafficking. PF-05175157 works by preventing immune cells from leaving lymph nodes, thus reducing their migration to sites of inflammation. This mechanism helps to decrease disease activity and flare-ups. Clinical trials are ongoing to evaluate its safety, efficacy, and potential in other inflammatory or autoimmune conditions.